(firstQuint)Combination of Bevacizumab and NK Immunotherapy for Recurrent Solid Tumors.

 By enrolling patients with recurrent solid tumors adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Bevacizumab and NK cells.

 The safety will be evaluated by statistics of adverse reactions.

 The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

.

 Combination of Bevacizumab and NK Immunotherapy for Recurrent Solid Tumors@highlight

The aim of this study is the safety and efficacy of Bevacizumab plus natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.

